Jean-Pierre Sommadossi, Atea Pharmaceuticals CEO
Atea's board rejects unsolicited cash offer from Tang Capital's Concentra
A week after confirming Tang Capital’s Concentra Biosciences proposed to buy Atea Pharmaceuticals, the Boston biotech said its board has rejected the unsolicited offer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
